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Abstract
Background: Paraneoplastic syndromes are serious immune caused diseases of the peripheral and/or central
nervous system associated with malignant neoplasm. Symptoms develop when antibodies against antigens
expressed by tumor cells cross-react with neuronal proteins. Antineuronal antibodies are usually examined in
patient’s sera while examination of the cerebrospinal fluid (CSF) often fails. Furthermore, the few previous
reports describing CSF data summarized different antineuronal antibodies and/or regarded patients with
different neurological symptoms as one group.
Methods: We retrospectively evaluated data of 18 patients with paraneoplastic syndromes due to anti-Hu
antibodies. The study aimed to differentiate patients with peripheral neuropathy and encephalitis by cerebrospinal
fluid (CSF) parameters including anti-Hu antibody titers.
Results: Our results confirm previous observations that serum titers of anti-Hu antibodies and standard CSF values
do not differ between patients with neuropathy and encephalitis. However, analysis of CSF anti-Hu titers and
calculating the intrathecal synthesis helped to discriminate between both groups.
Conclusion: In conclusion, our results indicate that patients even with one defined antineuronal antibody need to
be regarded separately depending on the involved location of the nervous system. We recommend incorporation
of anti-Hu analyses in the CSF and calculating the intrathecal synthesis in patients with anti-Hu syndrome.
Background
Paraneoplastic neurological syndromes (PNS) are rare
neurological disorders associated with malignant neo-
plasm [1]. The pathomechanisms are not caused by the
tumor itself, metastases, or the appropriate cancer
therapy. Instead, an immune-mediated remote cancer ef-
fect is considered. It is widely accepted that antibodies
against ectopic antigens expressed by tumor cells cross-
react with antigens of the nervous system and initiate an
immune cascade leading to neurodegeneration [2]. To
date, several “well-characterized” anti-neuronal anti-
bodies (Hu, Ri, Yo, CV2/CRMP5, Ma1, Ma2/Ta, and
Amphiphysin) were identified. The anti-Hu antibody has
been first described in 1985 in patients with small cell
lung cancer (SCLC) and sub-acute sensory neuropathy
[3] and has turned out as the most frequent paraneo-
plastic antibody [4]. The clinical spectrum of paraneo-
plastic anti-Hu syndromes is broad and different stages
and syndromes such as encephalomyelitis, limbic en-
cephalitis, subacute cerebellar degeneration, and sensory
neuropathy have been described [5]. The term enceph-
alomyelitis was introduced to define patients with cancer
and neurological symptoms including the whole nervous
system. However, this rather general term needs im-
provement since it does not describe patient’s key clin-
ical symptoms. It was thus recommended by others to
describe the paraneoplastic disorder according to the
leading focal syndrome that involves best patients signs
and symptoms e.g. brainstem encephalitis [5].
CSF analysis is crucial in the diagnosis of nervous sys-
tem infections and inflammatory driven autoimmune
diseases. CSF results such as cell count, glucose, total
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protein, and oligoclonal bands were previously reported
in few series of patients with anti-Hu associated para-
neoplastic syndromes [4]. Anti-Hu antibodies are usually
identified in patients sera while only few studies have, to
date, evaluated CSF titers and/or intrathecal synthesis of
anti-Hu antibodies [6, 7]. The literature still lacks
detailed CSF studies in patients with paraneoplastic anti-
Hu syndromes. Here, we performed a thorough evalu-
ation of clinical and laboratory data with special interest
on CSF. The aim of our study was to examine CSF
changes and intrathecal synthesis of anti-Hu antibodies
in patients with paraneoplastic peripheral neuropathy in
comparison to patients with paraneoplastic inflamma-
tion of the central nervous system.
Methods
Patients
The retrospectively evaluated data originate from 25 pa-
tients collected for routine diagnosis in the Hannover
Medical School in the time from 1996 to 2015. Only pa-
tients who fulfilled the diagnostic criteria of a paraneo-
plastic syndrome and were tested positive for anti-Hu
antibodies in serum by two independent analytical tech-
niques were included in the study. CSF was obtained in
all of these patients. The investigation was approved by
the local ethics committee of the Hannover Medical
School.
CSF and serum analytical procedures
CSF and serum were analysed by routine methods [8].
CSF leukocytes were counted manually with a Fuchs-
Rosenthal counting chamber. CSF total protein was de-
termined by the Bradford dye-binding procedure. IgG,
IgA, IgM, and albumin were measured in CSF and
serum in the same latex enhanced assay by kinetic neph-
elometry (Beckman Coulter IMMAGE). CSF-serum quo-
tients of IgG, IgA, IgM, and albumin were calculated [9].
The function of the blood–CSF barrier was estimated by
CSF-serum albumin quotients (QAlb). The age-adapted
upper limit of QAlb was calculated using the formula
QAlb = 4 + (age in years/15) [9]. Intrathecal synthesis of
IgG, IgA, and IgM was calculated based on the method
of Reiber-Felgenhauer referring the IgG, IgA, and IgM
quotients to the albumin quotient [9]. CSF oligoclonal
bands (OCB) were determined by isoelectric focusing
in polyacrylamide gels with consecutive silver staining.
All analyses were performed in the neuroimmunologi-
cal lab which participates in external quality control
programs [10].
Anti-Hu antibodies were detected by indirect immuno-
histochemistry using commercially available cerebellum
primate slides (INOVA Diagnostics) and immunoblots
with recombinant antigens (PNS-Blot, Ravo Diagnostika)
according to the instructions of the manufacturers. Anti-
Hu antibody titration was performed by indirect immuno-
histochemistry using cerebellum primate slides with in-
creasing dilutions. The starting dilution was 1:100 for
serum and 1:1 for CSF. To obtain an intrathecal synthesis
of anti-Hu antibodies the same approach was used to cal-
culate an antibody index (AI) in CNS inflammatory/infec-
tious diseases [11]. Anti-Hu IgG antibody specific index
(AI) was calculated according to the formula (CSF
anti-Hu IgG/serum anti-Hu IgG)/(CSF IgG total/
serum IgG total) [12]. In case of intrathecal synthesis
of IgG the following formula was used: (CSF anti-Hu
IgG/serum anti-Hu IgG)/Qlim. Qlim represents the
IgG fraction in CSF originating only from blood and
was calculated according to the individual’s albumin
quotient [12]. AI values > 2.0 indicate specific anti-
body synthesis in the CNS.
Statistical analysis
Fisher’s exact test was performed to assess the associ-
ation between dichotomous variables. For comparison of
two independent groups, the two-tailed unpaired two-
sided Mann–Whitney test was performed. For each




A total of 25 patients with neurological symptoms con-
firmative with a paraneoplastic syndrome were tested
positive for anti-Hu antibodies in serum by using the
immunoblot technique. Eighteen patients showed a clear
intense band while in seven patients only a borderline or
moderate intense band was found. By using immunohis-
tochemistry none of the latter seven patients showed an
anti-neuronal staining in the cerebellar tissue, and thus,
these patients were considered negative for anti-Hu anti-
bodies. The weak positive immunoblot band was rather
the result of a non-specific cross-reaction. In three of
these patients concurrent autoimmunological diseases
were known (systemic lupus erythematosus, Sjoegren’s
syndrome, neurosarcoidosis). Another patient presented
with acute lymphatic leukemia.
The remaining 18 patients with intense blot results
presented a clear anti-neuronal staining in the cerebellar
tissue. The typical staining for anti-Hu antibodies
showed a nuclear staining of neurons in the granular,
purkinje, and molecular cell layer (Fig. 1). Only these pa-
tients were considered positive for anti-Hu antibodies
and were included in our study. Patients were catego-
rized into two groups according to the location of
nervous system affection as identified by symptoms and
clinical signs leading to hospitalization: isolated peripheral
neuropathy or encephalitis. Patients with encephalitis
were further divided into two groups: rhombencephalitis
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or limbic encephalitis (Table 1). The cohort consisted of
eleven females and seven men. The median age of all
patients was 61 years with a range from 48 to 76 years.
Peripheral neuropathy associated with anti-Hu antibodies
In our cohort, eight patients showed peripheral neur-
opathy without signs of central nervous system (CNS)
involvement (Table 1). Duration of symptoms until
the diagnosis of anti-Hu syndrome was less than six
months in five patients and longer than 12 months in
only one patient.
At first presentation in our clinic, all eight patients
reported sensory abnormalities in terms of numbness
and tingle paresthesia. Involvement of both hands and
feet was found in five patients. In two patients, symp-
toms were initially restricted to either hands or feet
but extended to all extremities in the course of the
disease. One patient reported sensory deficits of both
feet only which remained localized in the lower ex-
tremities. At first examination weakness of extremities
was not found, but during the disease course, four
patients developed distal arm and leg palsy. Signs of
sensory ataxia were found in six patients at first
presentation but all patients developed relevant gait
disturbance in the course of disease.
Electrophysiological examinations revealed axonal dam-
age in all patients, while four patients showed signs of an
additional demyelinating damage. In all patients sensory
nerves were affected. Four patients showed an additional
damage of motor nerves.
Encephalitis associated with anti-Hu antibodies
Rhombencephalitis
In seven patients involvement of the rhombencephalon
defined as either cerebellar or brainstem symptoms was
found (Table 1). The duration from first neurological
symptom until diagnosis of anti-Hu syndrome was less
than six months in three patients and more than 12
months in four patients.
Four patients suffered from cerebellar and brainstem
symptoms including cerebellar ataxia, scanning dysarth-
ria, dysphagia, hemiparesis, oculomotor disturbance
(abducens palsy, internuclear opthalmoplegia), saccadic
eye movement, and/or nystagmus. In three patients
brainstem symptoms without cerebellar involvement
were found including oculomotor disturbance (abducens
palsy), hemiparesis, and hemihypesthesia. One patient
Fig. 1 Anti-Hu staining in the primate cerebellum as demonstrated by immunohistochemistry. Cerebellar tissues were either incubated with
serum of a control healthy patient (left) or with serum of a patient with a paraneoplastic syndrome due to anti-Hu antibodies

















All patients 11/18 61 (48–76) 4 (1–36) 15/18 16/18 14/18
Peripheral neuropathy 5/8 59 (54–76) 3 (1–36) 7/8 7/8 5/8
Encephalitis 6/10 61 (48–74) 4 (1–15) 8/10 9/10 9/10
Rhombencephalitis 3/7 61 (48–73) 13 (3–15) 6/7 6/7 6/7
Limbic encephalitis 3/3 55, 61, 74 1, 3, 4 2/3 3/3 3/3
p value 1.0 0.6 0.5 1.0 1.0 0.3
Age and duration of symptoms until diagnosis are presented by median with lowest and highest values. P values indicate comparison between peripheral
neuropathy and encephalitis
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with brainstem symptoms reported numbness on the left
side of the face, on the left arm and leg. In this patient,
MRI showed a cervical lesion indicating an additional
myelitis.
Only one patient presented with symptoms of isolated
CNS involvement. The other six patients reported
numbness and tingle paresthesia of hands and feet as
first symptoms. In these patients a concomitant periph-
eral neuropathy was found. In the disease course these
patients developed an additional distal palsy of hands
and feet.
Limbic encephalitis
Limbic encephalitis was diagnosed in three patients
(Table 1). The duration from onset of neurological
symptoms until diagnosis of a paraneoplastic syndrome
ranged from 1 to 4 months. Symptoms included aggres-
sive behavior, anxiety, disorientation, and a mnestic syn-
drome. Two patients suffered from focal epileptic
seizures. In both patients EEG showed epileptic foci
(right hemisphere or parietal left). One patient devel-
oped general seizures and status epilepticus occurred
three times during the disease course. Only one patient
suffered from an additional sensory neuropathy before
onset of encephalitis.
CSF findings in peripheral neuropathy
Three patients showed a slightly elevated CSF cell count
between 7 and 28 cells/μl, while in five patients normal
cell counts were found (Table 2, Fig. 2). CSF lactate con-
centrations were normal in all patients. Total protein
was increased in four patients. Measurements of QAlb,
which is the best indicator for a blood-CSF barrier dys-
function, revealed age-corrected increased values in six
patients. Barrier impairment was severe in 3 patients
(QAlb >20) and mild to moderate in the other three
patients.
Oligoclonal bands restricted to the CSF were found in
only three patients (38 %) indicating intrathecal IgG syn-
thesis. One of these patients showed a combination of
oligoclonal bands restricted to the CSF and identical
oligoclonal IgG bands in CSF and serum (type 3). Identi-
cal oligoclonal IgG bands in CSF and serum were found
in three patients with peripheral neuropathy. Intrathecal
synthesis of immunoglobulins of either IgM, or IgG, or
IgA occurred in only two patients. Intrathecal synthesis
of IgM as calculated by the method of Reiber-
Felgenhauer was found in one patient and IgG synthesis
in another one patient. Both patients presented oligoclo-
nal bands restricted to the CSF.
CSF findings in encephalitis
Five patients with encephalitis showed a slightly elevated
cell count between 7 and 11 cells/μl, while in the other
five patients normal cell counts were found (Table 2,
Fig. 2). All patients had normal lactate concentrations.
Total protein was increased in two patients. A blood-
CSF barrier dysfunction measured by QAlb was detected
in these two patients. Barrier impairment was severe in
one patient (QAlb >20) and mild in the other patient.
Oligoclonal bands restricted to the CSF were found in
all ten patients (100 %) indicating intrathecal IgG syn-
thesis. Three of these patients showed a combination of
oligoclonal bands restricted to the CSF and identical oli-
goclonal IgG bands in CSF and serum (type 3). Intra-
thecal synthesis of immunoglobulins of either IgM, or
IgG, or IgA occurred in five patients. One of these pa-
tients presented with a combined three-class reaction of
intrathecal synthesis of IgG, IgM, and IgA. One patient
showed a two-class reaction of intrathecal synthesis of
IgG and IgA. The remaining three patients showed an
isolated IgG synthesis.
Anti-Hu antibody titers in serum and CSF
Serum anti-Hu titers were available from all 18 patients
and were similar in patients with peripheral neuropathy
(between 1:1600 and 1:12.800) and patients with CNS
involvement (1:800 and 1:12.800; Fig. 3). CSF anti-Hu ti-
ters were available from 6/8 patients with neuropathy
and from 8/10 patients with encephalitis. As shown in
Fig. 3, anti-Hu titers in the CSF tended to lower values
in patients with peripheral neuropathy (between 1:1 and














All patients 8/18 6/18 8/18 6/18 2/18 2/18 14/18
Peripheral neuropathy 3/8 4/8 6/8 1/8 1/8 0/8 3/8
Encephalitis 5/10 2/10 2/10 5/10 1/10 2/10 10/10
Rhombencephalitis 4/7 1/7 1/7 3/7 1/10 1/7 7/7
Limbic encephalitis 1/3 1/3 1/3 2/3 0/3 1/3 3/3
p value 0.7 0.3 0.1 0.2 1.0 0.5 0.01
P values indicate comparison between peripheral neuropathy and encephalitis
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1:80) as compared to patients with encephalitis (between
1:40 and 1:200).
The antibody index (AI) was calculated with the aim
to indicate an intrathecal synthesis of anti-Hu anti-
bodies. Intrathecal synthesis of anti-Hu antibodies was
found in all eight patients with encephalitis (Fig. 3). In
contrast, in patients with peripheral neuropathy intra-
thecal synthesis of anti-Hu antibodies (>2) did not occur.
However, two patients showed borderline values (AI of
1.67 and 1.97).
Neuroimaging findings
Cranial MRI confirmed the diagnosis of limbic encephal-
itis in one patient showing T2 weighted lesions in both
temporal lobes. In one patient with rhombencephalitis
MRI depicted a T2 weighted lesion in the spinal cord. In
the other two patients with limbic encephalitis and all
seven patients with brainstem encephalitis MRI did not
reveal radiological sings of inflammation in the brain. In
these patients, only signs of brain atrophy and unspecific
vascular lesions unrelated to a paraneoplastic disease
were found. Cerebral metastases and leptomeningeal en-
hancement as a sign of neoplastic meningitis were nei-
ther detected in patients with rhombencephalitis nor
limbic encephalitis.
Malignancy
In 16 patients (89 %) with anti-Hu syndrome a malig-
nant tumor was either known or diagnosed consecu-
tively (Table 1). In three patients an underlying
malignancy was known before the diagnosis of anti-Hu
syndrome. In two of these patients lung cancer (SCLC
and non-small cell lung cancer (NSCLC)) was diagnosed
1 month before, while another patient suffered from
breast cancer since 5 months.
After diagnosis of anti-Hu syndrome, tumor screening
revealed new lung or breast malignancy in 13 patients.
Histological analyses revealed SCLC in ten patients,
NSCLC in two patients, and breast cancer in one pa-
tient. In eight patients new malignancy was found
already at the time of initial hospitalization due to anti-
Hu syndrome. In four patients tumor was found within
Fig. 2 Cerebrospinal fluid results in patients with anti-Hu syndrome. Graphs show the distribution of cell count (a), total protein (b), and albumin
CSF/serum quotients (c) in patients with peripheral neuropathy and encephalitis. The bars represent the median values in each group
Fig. 3 Serum and cerebrospinal fluid anti-Hu titers. In a, distribution of serum anti-Hu titers in patients with peripheral neuropathy and encephal-
itis is shown. In b, anti-Hu titers are shown in the cerebrospinal fluid. In c, antibody index of anti-Hu specific IgG is shown which indicates specific
intrathecal antibody synthesis. Antigen index values >2.0 indicate an intrathecal synthesis
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12 months, while in one patient tumor was found after
5 years. Two patients with newly diagnosed NSCLC had
a positive history of breast cancer. Breast cancer was
found 4 and 9 years before, respectively, and was consid-
ered to be in remission in both patients.
In one patient malignancy was not found at the time
point of anti-Hu syndrome and patient did not return
for follow up. In another one patient malignancy was
not found within a follow-up of 20 months.
Metastases were found in one patient with lung
cancer (in the ribs) and one patient with breast
cancer (liver). In the other patients no metastases
were found.
Discussion
In this retrospective study, we analyzed characteristics of
clinical and immunological features in patients with
paraneoplastic syndromes associated with anti-Hu anti-
bodies. Our results show crucial differences in CSF re-
sults depending on whether the peripheral or central
nervous system is affected. We found that intrathecal
synthesis of anti-Hu antibodies discriminates between
patients with isolated peripheral neuropathy and patients
with encephalitis.
It is widely accepted that CSF analysis is essential in
the diagnosis of paraneoplastic syndromes [5]. However,
there is only few data regarding CSF results in patients
with anti-Hu syndromes. Indeed, one large study in-
cluded 170 patients from the PNS European database di-
agnosed in Europe after 2000 [4]. However, CSF results
are incomplete and oligoclonal bands were studied in 73
patients only (43 %). Furthermore, patient’s information
is lacking and patients with anti-Hu syndrome were
regarded as one group. Thus, the interpretation of oligo-
clonal bands (positive in 59 % of these patients) under-
lies severe limitations. The main limitation of other
reports is the fact that paraneoplastic syndromes with
different anti-neuronal antibodies were summarized
and/or regarded as one group [13, 14]. Here, we show
that even in patients with one defined antineuronal anti-
body immunological results need to be interpreted
separately depending on the involved location of the
nervous system. In our cohort patients suffered either
from isolated peripheral neuropathy or encephalitis
(rhombencephalitis or limbic encephalitis). CSF analysis
revealed oligoclonal bands indicating intrathecal IgG
synthesis in all ten patients with encephalitis associated
with anti-Hu antibodies (100 %). In contrast, in patients
with peripheral neuropathy oligoclonal bands were
found infrequently (38 %). CSF standard parameters
such as cell count and blood-CSF barrier dysfunction
(albumin ratio, total protein) were similarly distrib-
uted in both groups and do not help to differentiate
between them.
It is known that serum titers of anti-Hu antibodies do
not correlate with disease progression. In our work, we
confirm these previous observations as we found similar
serum titers in patients with peripheral and central ner-
vous system involvement. In contrast, all patients with
encephalitis displayed an intrathecal synthesis of anti-Hu
antibodies, while patients with peripheral neuropathy
did not. We hypothesize that these results indicate dif-
ferent disease progression in isolated peripheral neur-
opathy and encephalitis. It is well known that anti-Hu
antibodies react with nuclei of both peripheral and cen-
tral nervous system neurons [15]. In our cohort, in the
majority of patients with encephalitis the paraneoplastic
syndrome started with peripheral sensory neuropathy.
Since the malignancy is found in the periphery outside
the CNS it seems to be obvious that anti-Hu antibodies
first react with peripheral neurons of the dorsal root
ganglia resulting in peripheral sensory neuropathy.
During the disease course in some patients plasma cells
within the CNS start to produce anti-Hu antibodies as
well (which is measured as intrathecal synthesis of this
antibody) consequently resulting in encephalitis. The
pathomechanisms of this crossover are not known. We
can only speculate that peripheral antibodies passively
diffuse into the CNS and then react with neurons. This
reaction might initiate an immune cascade in which
local B cells differentiate into plasma cells and produce
anti-Hu antibodies locally in the CNS. However, this
crossover does not occur in all patients. It was described
that some patients with peripheral neuropathy due to
anti-Hu antibodies do not develop encephalitis [16].
Neuropathological brain studies of patients with anti-
Hu encephalitis revealed severe loss of neurons in
combination with inflammatory infiltrates with predom-
inantly T lymphocytes [17]. These inflammatory signs
and neurodegeneration suggest that early efficient treat-
ment might be beneficial for the clinical outcome. We
hypothesize that the treatment benefit might be of par-
ticular success in patients with isolated peripheral neur-
opathy prior to additional encephalitis. Analysis of the
CSF with determination of intrathecal synthesis of anti-
Hu antibodies presents a useful tool to discriminate
between these both groups of patients with and without
involvement of the CNS. Our findings might be thus
relevant for the treatment of these patients.
Conclusion
Our data show that patients with paraneoplastic
syndromes due to anti-Hu antibodies need to be
regarded separately depending on the involvement of
the peripheral or central nervous system. CSF analysis
with determination of intrathecal synthesis of anti-Hu
antibodies presents an important tool to discriminate
these patients. However, with respect to the limited
Schwenkenbecher et al. BMC Neurology  (2016) 16:136 Page 6 of 7
group size a larger multicenter study is needed to
confirm our results.
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